Home/Filings/4/0001209191-20-037339
4//SEC Filing

Gasmi Mehdi 4

Accession 0001209191-20-037339

CIK 0001501756other

Filed

Jun 16, 8:00 PM ET

Accepted

Jun 17, 5:14 PM ET

Size

14.7 KB

Accession

0001209191-20-037339

Insider Transaction Report

Form 4
Period: 2020-06-15
Gasmi Mehdi
VP, Pharmaceutical Development
Transactions
  • Sale

    Common Stock

    2020-06-15$21.01/sh5,000$105,042279,442 total
  • Exercise/Conversion

    Common Stock

    2020-06-15$4.80/sh+10,000$48,000284,442 total
  • Sale

    Common Stock

    2020-06-15$21.93/sh1,416$31,047278,026 total
  • Sale

    Common Stock

    2020-06-15$23.00/sh3,425$78,787274,601 total
  • Sale

    Common Stock

    2020-06-15$23.59/sh159$3,751274,442 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-06-1510,000118,000 total
    Exercise: $4.80Exp: 2026-02-11Common Stock (10,000 underlying)
Footnotes (6)
  • [F1]Shares sold pursuant to a 10b5-1 plan.
  • [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.50 to $21.49. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $21.51 to $22.42. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F4]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $22.55 to $23.39. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F5]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $23.57 to $23.63. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F6]Fully vested and exercisable.

Issuer

Adverum Biotechnologies, Inc.

CIK 0001501756

Entity typeother

Related Parties

1
  • filerCIK 0001614875

Filing Metadata

Form type
4
Filed
Jun 16, 8:00 PM ET
Accepted
Jun 17, 5:14 PM ET
Size
14.7 KB